Research groups
Parvinder Aley
Director of Operations (OVG)
Parv joined the Oxford Vaccine Group in May 2016. She has a PhD in Cellular Physiology from the University of Leeds. Subsequently she moved to Oxford where she has worked at the University for the past 10 years, initially as a researcher and more recently as a Contracts Specialist. As Operational Manager, she is responsible for the strategic management of the group with the aim to facilitate research on the development and implementation of vaccines.
Recent publications
-
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.
Journal article
Ogbe A. et al, (2022), JCI Insight
-
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Journal article
Costa Clemens SA. et al, (2022), Lancet
-
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Journal article
Dejnirattisai W. et al, (2022), Cell
-
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Journal article
Feng S. et al, (2021), Nature Medicine
-
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2021), Lancet